NASDAQ: LYRALyra Therapeutics Inc Stock
$11.34-0.51 (-4.3%)
Updated Jun 13, 2025
LYRA Price
$11.34
Fair Value Price
N/A
Market Cap
$15.03M
52 Week Low
$3.81
52 Week High
$37.50
P/E
-0.19x
P/B
3.88x
P/S
7.01x
PEG
N/A
Dividend Yield
N/A
Revenue
$1.19M
Earnings
-$79.53M
Gross Margin
100%
Operating Margin
-6,708.95%
Profit Margin
-6,711.4%
Debt to Equity
13.54
Operating Cash Flow
-$56M
Beta
0.56
Next Earnings
Aug 12, 2025
Ex-Dividend
N/A
Next Dividend
N/A
LYRA Overview
Lyra Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase II clinical trial; and LYR-220 for CRS patients with and without nasal polyps. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine LYRA's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
F
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
LYRA
Ranked#217 of 464
Ranked#217 of 464
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $8.18 | A | |
| $41.59 | A | |
| $23.53 | A |
Be the first to know about important LYRA news, forecast changes, insider trades & much more!
LYRA News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how LYRA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
LYRA is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
LYRA is good value based on its book value relative to its share price (3.88x), compared to the US Biotechnology industry average (4.66x)
P/B vs Industry Valuation
LYRA is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more LYRA due diligence checks available for Premium users.
Valuation
LYRA fair value
Fair Value of LYRA stock based on Discounted Cash Flow (DCF)
Price
$11.34
Fair Value
-$2.80
Undervalued by
505.10%
LYRA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
LYRA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.19x
Industry
-108.97x
Market
31.36x
LYRA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
3.88x
Industry
4.66x
LYRA is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
LYRA's financial health
Profit margin
Revenue
$183.0k
Net Income
-$8.5M
Profit Margin
-4,670.5%
LYRA's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
LYRA's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$56.3M
Liabilities
$52.4M
Debt to equity
13.54
LYRA's short-term assets ($33.91M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
LYRA's long-term liabilities ($40.97M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
LYRA's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
LYRA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$8.8M
Investing
$0.0
Financing
$0.0
LYRA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
LYRA vs Biotech Stocks
Lyra Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.